Drugmakers, insurers, hospitals, pharmacies, medical devices, clinical updates, and healthcare business leaders.
A market report says Johnson & Johnson (JNJ) has moved to buy Firefly Bio in a deal valued at about $1 billion in cash, as investors weigh valuation, pipeline risk, and how new oncology bets fit into the company’s broader healthcare portfolio.
THE APEX TIMES
THE APEX TIMES
A recent market note flagged strong recent performance in CVS Health stock, but offered limited specifics on the operational drivers behind Q1 results, leaving investors to weigh sustainability versus near-term momentum.
THE APEX TIMES
A fresh Wall Street push to own Eli Lilly (LLY) is gaining traction as June volatility whips markets and GLP-1 demand expectations lift the stock. Still, much of the bullish case depends on how durable results remain beyond the current hype cycle.
THE APEX TIMES
Guinness Global Innovators’ Q1 2026 investor letter for its Global Equity Income Fund highlighted Johnson & Johnson, pointing to improving market sentiment rather than company-specific guidance.
THE APEX TIMES
In a market commentary carried by Yahoo Finance, Jim Cramer said he prefers drug-related stocks over parts of the tech complex and cited Johnson & Johnson as an example while discussing his current stance toward the drug sector.
THE APEX TIMES
CVS Health shares are trading at their highest level over the past year, according to a recent market roundup. The key question is whether the move reflects improving fundamentals or simply market optimism.
THE APEX TIMES
The drugmaker highlighted long-term survival outcomes for two oncology medicines, BRAFTOVI and TALZENNA, at the annual ASCO meeting, reinforcing its pipeline priorities while analysts weigh what the results mean for future revenue and share value.
THE APEX TIMES
A Yahoo Finance-linked market column says CVS Health is among the stocks getting the most attention from Zacks.com users, prompting renewed focus on what could drive the next phase for the healthcare retailer and pharmacy operator.
THE APEX TIMES
The bank said Eli Lilly’s pipeline momentum and recent regulatory and coverage updates around obesity treatment are sustaining investor interest.
